The present study aimed to determine the clinical benefits to critically ill patients with severe sepsis of receiving parenteral fish-oil-based lipid emulsion as adjuvant treatment.
Introduction
Severe sepsis and septic shock are major causes of death in intensive care medicine worldwide, and have a high mortality rate. Proinflammatory cytokine cascades and complex autotoxic mediators following microbial infection with sepsis can cause life-threatening organ sequelae and death. 1, 2 The high mortality rate has prompted intensive worldwide debate and research that has resulted in the development of useful scientific therapeutic guidelines. 3 A fish-oil-based lipid emulsion (FOBLE) is a product that is enriched with ω-3 fatty acids, which are long-chain polyunsaturated fatty acids and include eicosapentaenoic acid and docosahexaenoic acid. Several large studies on various patient subgroups have demonstrated that administration of FOBLE or ω-3 fatty acids increases beneficial outcomes. The diseases treated include cardiovascular diseases, autoimmune diseases, atopic dermatitis, respiratory distress; they are also used in patients undergoing abdominal surgery, as well as HIV-infected patients with antiretroviral therapy. [4] [5] [6] [7] [8] [9] Over the past decade, FOBLE treatment of sepsis has been explored widely using animal models and human subjects. It has been shown that FOBLE administration in sepsis seems to be associated with improvements caused by better leukocyte functionality and increased generation of lipid-mediators, which seem to modulate cytokine release, and ultimately to reduce the processes involved in inflammation. 10, 11 The immunomodulating effects of FOBLE probably have an impact on anti-inflammatory processes, and patients should thus have a beneficial outcome in a clinical setting. However, such clinical effects have not been studied in Chinese people. Therefore, we performed a prospective study to assess the clinical outcomes when FOBLE was used as an adjunctive treatment for Taiwanese patients with severe sepsis in an intensive care unit (ICU).
Patients and methods

Study design and protocol
The study was performed in the 42-bed general ICU of Landseed Hospital, a 580-bed primary and referral teaching hospital in the northern region of Taiwan. The study design was a prospective, randomized, double-blind, placebocontrolled clinical trial. The protocol was approved by the institutional review board of Landseed Hospital and registered on ClinicalTrial.gov [NCT00634075] . Between April 2008 and March 2009, patients admitted to the ICU with a main diagnosis of severe sepsis were enrolled in the study. Written informed consent was obtained from all participants or their authorized representatives. By the blocks of four randomization method, the enrolled patients were assigned to receive supplementation with FOBLE (10% Omegaven; Fresenius-Kabi, Bad Homburg, Germany) as the study group or placebo (0.9% normal saline) as the control group, via a central venous catheter; this was carried out within 24 hours of ICU admission, with a dosage of 100 mL/day for 5 days. Each infusion was started at mid-day or midnight and lasted for 6 hours.
The prescription procedures were performed as follows: the apparatus was completely wrapped with opaque cloth bandage tape, including burette, drip chamber, catheter and adaptor, up to the patient's central venous catheter, to ensure that the patient, physician and medical staff were unable to ascertain the contents of the infusor. Under aseptic technique, 100 mL 10% Omegaven or 0.9% normal saline was extracted using a syringe by a research assistant and injected into the burette after priming with approximately 20 mL 0.9% normal saline. The apparatus was then taken to the patient's bedside, and an infusion pump was used to regulate the delivery rate at 17 mL/hr, and was set to alarm when the infusor had infused 100 mL. Finally, 20 mL of 0.9% normal saline was injected into the burette to flush the system. The entire apparatus was disposed of when each infusion was completed. The whole process was repeated for each infusion.
A bottle of 10% Omegaven emulsion contained 10.0 g refined fish oil, with fatty acids content as follows: eicosapentaenoic acid, 12.5-28.2 g/L; docosahexaenoic acid, 14.4-30.9 g/L; myristic acid, 1.0-6.0 g/L; palmitic acid, 2.5-10.0 g/L; palmitoleic acid, 3.0-9.0 g/L; stearic acid, 0.5-2.0 g/L; oleic acid, 6.0-13.0 g/L; linoleic acid, 1.0-7.0 g/L; linolenic acid, ≤ 2.0 g/L; octadecatetraenoic, 0.5-4.0 g/L; eicosaenoic acid, 0.5-3.0 g/L; arachidonic acid, 1.0-4.0 g/L; docosaenoic acid, 1.5 g/L; docosapentaenoic acid, 1.5-4.5 g/L; and other fatty acids, 10.51 g/L.
A clinical diagnosis of sepsis was defined as systemic inflammatory response syndrome with a documented infection. Systemic inflammatory response syndrome is manifested by two or more of the following four variables: (1) hyperthermia > 38.3°C or hypothermia < 36°C; (2) tachycardia (> 90 beats/min); (3) tachypnoea (rate ≥ 20 breaths/ min) or hypoxia (oxygen saturation < 90% or need for oxygen supplementation of ≥ 0.4 fraction of inspired oxygen to maintain adequate saturation); and (4) leukocytosis (white blood cell count > 12.0×10 9 /L), leukopenia (white blood cell count < 4 × 10 9 /L), or immature or band forms > 10%. Severe sepsis was defined as sepsis with the additional complication of acute organ dysfunction, hypotension, or hypoperfusion that might cause abrupt changes in the patient's mental status, the presence of lactic acidosis, or acute oliguria (urine < 0.5 mL/kg/hr). Septic shock was defined as persistent arterial hypotension despite adequate volume resuscitation (20-40 mL/kg). 12, 13 The exclusion criteria for this study included patient age < 18 years old; pregnancy; treatment with immunosuppressive drugs; treatment with hydrocortisone > 300 mg/day at admission; infection with human immunodeficiency virus; plasma triglyceride concentration > 400 mg/dL; cirrhotic liver and/or acute hepatitis; chronic renal failure and/or end stage renal disease; acute myocardial infarction; ■ KHOR et al ■ recent stroke; presence of an irreversible underlying disease that is anticipated to be rapidly fatal, or an allergic reaction against fish or egg proteins.
Data collection and laboratory methods
Baseline characteristics included demographic data, body mass index, information on pre-existing conditions, infectious diagnosis, comorbidity, causative pathogen, haemography and other laboratory tests; these were assessed within 24 hours of admission and before the infusion began. Blood was collected from participants before the first lipid preparation was infused, and this was used as a baseline. Blood was then collected on day 1, day 3, day 5 and day 7 at 2 hours after lipid infusion.
Clinical severity was calculated at baseline, and on day 1, day 3, day 5 and day 7, using the Acute Physiology and Chronic Health Evaluation (APACHE) II score, APACHE III score, and Simplified Acute Physiology Score (SAPS) II. [14] [15] [16] The serum concentration of tumour necrosis factor (TNF)-α was determined by sandwich enzymelinked immunosorbent assay (BioSource; Invitrogen, Carlsbad, CA, USA), whereas that of procalcitonin was determined by immunoluminometric assay (Brahms Diagnostica, Berlin, Germany). These measurements were also obtained at baseline as well as day 1, day 3, day 5 and day 7. Patients were followed up for 28 days after the start of infusion or until death.
Statistical analysis
Statistical analysis was carried out using SPSS version 14.0 (SPSS, Chicago, IL, USA). Results are presented as the mean and standard deviation. The demographic, clinical and laboratory data, and the various clinical scores (APACHE II, APACHE III and SAPS II) were compared between the groups using nonparametric statistical testing. Comparison of continuous variables used the Mann-Whitney U test, and comparison of dichotomous variables used the χ 2 or Fisher's exact test. Score reduction within each group on day 1, day 3, day 5 and day 7 was calculated by subtracting the baseline value, and was measured for both groups. The differences in the reduced scores between the groups were further assessed using the Mann-Whitney U test. The differences in ICU and hospital stay between the groups were determined using the log-rank test, and a Kaplan-Meier curve was constructed. A difference with the two-tailed tests of p < 0.05 was considered statistically significant.
Results
Demographic characteristics
During the study period, a total of 28 patients were enrolled for analysis. There were 20 men and 8 women, and their mean age was 69.3 ± 16.2 years (range: 32-94 years). Fourteen patients were randomly assigned to the study group and the others formed the control group. In the control group, one patient was withdrawn on day 2 due to the appearance of acute hepatitis (glutamate oxaloacetate transaminase, 1748 U/L, glutamic pyruvic transaminase, 820 U/L; Figure 1 ).
Baseline characteristics
The demography, body mass index and associated diseases across the groups are shown in Table 1 . Four patients had severe sepsis and 10 had septic shock in the study group; 2 patients had severe sepsis and 12 had septic shock in the control group. In the study group, the clinical diagnosis of the patients was pneumonia in eight cases (1 patient additionally had an anal abscess), infectious colitis in two cases, as well as one case each of lung abscess, urinary tract infection (UTI), liver abscess and endocarditis. In the Completely followed up for 28 days (n = 14)
Completely followed up for 28 days (n = 13) control group, there were seven cases of pneumonia, two of empyaema, one of primary bacteraemia, and six of UTI. Two patients had concurrent pneumonia and UTI. In the study group, nine patients developed acute respiratory failure (eight required invasive mechanical ventilator supplementation), five had various degrees of consciousness disturbance, and four had acute renal insufficiency. In the control group, six had acute respiratory failure (5 required invasive mechanical ventilator supplementation), two had consciousness disturbance, and six had acute renal insufficiency ( group and all 9 in the control group were prescribed initially with adequate antibiotics ( Table 2 ). The baseline laboratory findings and causative pathogens across the groups are shown in Tables 3 and 4 . In addition, all patients tolerated well a 5-day course of FOBLE infusion, and the mean daily dosage of FOBLE was 0.18 ± 0.04 g/kg (range, 0.12-0.26 g/kg). All participants survived the following 28 days. Table 2) . Following treatment, the clinical scores for APACHE II, APACHE III and SAPS II showed a decline for both groups on day 1, day 3, day 5 and day 7, but the measures did not show a significant difference between the groups (Figure 2 ). Regarding score reduction, the APACHE II score showed a significant difference between the study and control groups on day 3 (10.1 ± 5.9 vs.
Clinical severity assessment
3.9 ± 3.7; p = 0.004), day 5 (11.2 ± 6.1 vs. 6.6 ± 4.6; p = 0.032); and day 7 (12.9 ± 6.7 vs. 7.3 ± 5.1; p = 0.03) ( Figure 3A ). APACHE III score and SAPS II revealed significant differences between the groups on day 7 (48.3 ± 28.9 vs.
28.5 ± 16.3; p = 0.028 and 29.3 ± 14.3 vs. 15.9 ± 10.8; p = 0.019), respectively ( Figures 3B and 3C ).
Serum TNF-α and procalcitonin levels
The mean serum TNF-α level, on statistical comparison between study and control groups, showed a value of ) reductions on day 1, day 3, day 5 and day 7 between groups. *All p values were significant for APACHE II on day 3 (p = 0.004), day 5 (p = 0.032) and day 7 (p = 0.03), and APACHE III score (p = 0.028) and SAPS II (p = 0.019) on day 7. APACHE = Acute Physiology and Chronic Health Evaluation; SAPS = Simplified Acute Physiology Score.
44.5 ± 32.0 versus 29.4 ± 21.8 (p = 0.203) at baseline; on the following day 1, the values were 19.6 ± 19.6 versus 16.9 ± 17.9 (p = 0.795); on day 3, the values were 11.0 ± 17.6 versus 8.3 ± 12.6 (p = 0.802); on day 5, the values were 5.6 ± 10.8 versus 9.6 ± 10.1 (p = 0.335); and on day 7, the values were 3.5 ± 9.2 versus 4.2 ± 4.7 (p = 0.295) ( Figure 4A) . The serum procalcitonin level between the groups at baseline was 10.5 ± 10.4 versus 56.7 ± 79.3 (p = 0.423); on the following day 1, the values were 7.7 ± 8.1 versus 53.2 ± 59.4 (p = 0.055); on day 3, the values were 3.2 ± 3.1 versus 17.9 ± 15.0 (p = 0.018); on day 5, the values were 1.2 ± 1.1 versus 4.6 ± 2.5 (p = 0.011); and on day 7, the values were 0.5 ± 0.3 versus 1.7 ± 1.5 (p = 0.028) ( Figure 4B ).
Length of ICU and hospital stay
The mean (with a 95% confidence interval) length of ICU stay and hospitalization were 10.3 (6-14.5) days and 19.6 (15.9-23.4) days, respectively, in the study group, and 8.4 (5-11.8) days and 17.5 (14.3-20.6) days for the control group; with p values of 0.573 and 0.299, respectively ( Figure 5 ).
Discussion
Overall, the baseline clinical features and laboratory findings did not differ significantly between the groups. All patients were treated according to the surviving sepsis The curves were constructed by the Kaplan-Meier method. All participants were followed up for 28 days. When compared between the groups using the log-rank test, there were no significant differences in terms of length of stay in the intensive care unit (p = 0.573) or length of hospitalization (p = 0.299). ICU = intensive care unit. campaign guidelines, 3 including fluid resuscitation, early goal-directed therapy, broad-spectrum antibiotic prescription, and blood sugar control, as well as additional adjuvant treatment with parenteral FOBLE of 10% Omegaven in the study group. As shown in Table 2 , more patients in the study group required vasopressor and invasive mechanical ventilation, and overall, their clinical scores seemed to be more serious than those of the control group, however, this difference did not reach statistical significance. The diagnoses in the study group showed a relatively higher diversity compared with the control group ( Table 2) . Two of the patients in the study group were not initially prescribed with adequate antibiotics, but the antibiotics were adjusted accordingly when the test results became available. The patients in each group who had no documented culture data also showed clinical improvement after empirical antibiotic treatment. One patient, who was withdrawn from the control group on day 2, was thought to have acute hepatitis followed by compromised shock.
As sepsis proceeds, there are metabolic changes in body lipids, increased production of proinflammatory cytokines, as well as increased pathophysiological oxidation of lipids. In this context, Mayer et al 17 have reported that there was a marked and rapid increase in the free plasma eicosapentaenoic acid (average, 35 μmol/L) and docosahexaenoic acid (average, 65 μmol/L) levels following parenteral 10% Omegaven FOBLE administration; this was thought to produce anti-inflammatory and immunomodulatory effects. In addition, Heller et al 7 have reported that > 0.1 g/kg/day 10% Omegaven FOBLE resulted in clinically beneficial effects. In our study, the prescribed dosage was 0.12-0.26 g/kg/day; this was thought to be optimal, and sufficient to be active for pharmacological intervention. All patients tolerated well a 5-day course of parenteral FOBLE infusion, and there were no significant adverse effects, although one patient in the study group did complain of a fish oil taste during infusion.
The APACHE II and APACHE III scores and SAPS II results are the major adult severity assessment tools in ICUs; Afessa et al 18 have shown that the area under the receiver-operating characteristic curve was 0.863, 0.90 and 0.88, respectively. These scores are generally applied in mortality prediction, as well as evaluating clinical evolution. As shown in Figure 2 , the clinical scores within the groups decreased in parallel with treatment, but there were no significant differences between the groups. However, in terms of score reduction, the study group was associated with a significant decrease in APACHE II scores on day 3, day 5 and day 7, as well as APACHE III score and SAPS II on day 7 (Figure 3 ). The results agree in part with previous studies in which fish oil supplements were associated with increased bacterial killing, maintenance of blood flow in the intestines, and modified leukocyte activity, 19, 20 some of which might have given rise to clinical improvement among critically ill septic patients who had received FOBLE adjuvant treatment. In this context, it is important to note that reducing clinical severity should logically lead to increased patient self-confidence during recovery, and this might possibly avoid undesired comorbidity due to sepsis.
Serum procalcitonin has been used as a valuable inflammatory marker for severe sepsis, and generally corresponds well with the degree of sepsis. 21, 22 In this study, the serum procalcitonin level was significantly decreased in the study group on day 3, day 5 and day 7 ( Figure 4B ). Application of FOBLE might facilitate the resolution of inflammation via regulation of transcription factor nuclear factor-κB activity and an increase in the level of ω-3 fatty-acid-derived resolvins. 23 Another reported by Pacht et al 24 has shown that inflammatory mediators are reduced in the bronchoalveolar lavage fluid from patients with acute respiratory distress syndrome after administration of ω-3 fatty acids. The results of the present study suggest that 10% Omegaven exerts an anti-inflammatory effect. Specifically, TNF-α, an early phase proinflammatory cytokine, ought to be elevated in the blood when sepsis occurs, because serum concentration and persistence levels are well correlated with the risk of multiple organ failure and mortality. 25 In our study group, the mean serum TNF-α levels were higher initially, but declined more in the following days when compared with those in the control group. This was an important effect, although there was no overall statistically significant difference between the groups. These results are different from those of Mayer et al, 17, 26 who have found that TNF-α levels are significantly suppressed by FOBLE; one important difference perhaps is that we used 0.9% normal saline as a placebo. Some studies have reported that treatment with FOBLE is able to shorten the length of ICU and hospital stays in surgical patients. 7, 8 However, in the present study, ICU and hospital stays were not significantly different when the study and control groups were compared ( Figure 5 ). Four patients were censored following 28 days in the study group. Of these, one needed prolonged antibiotic therapy due to endocarditis; one unfortunately developed hypoglycaemia with metabolic encephalopathy on a non-ICU ward, which resulted in prolonged hospitalization; and two were difficult to wean off the ventilator, which prolonged the stay in the ICU and extra days of hospitalization. Two were censored in the control group, with one needing prolonged antibiotic treatment for complicated empyaema, and another needing prolonged ventilator use due to chronic obstructive pulmonary disease with pneumonia. In addition to the clinical severity of the disease entity, it is clear that patients' various associated diseases, their comorbidity, and/or the duration of their course of antibiotics all significantly influence the length of stay in the ICU and the number of days in hospital.
Due to a constellation of selective criteria for participant enrolment, the case number was limited in this study. To avoid an extreme statistical bias, nonparametric statistical testing was used to compare the various variables between the groups. In addition, the fact that the study was conducted in only one ICU setting means that it might not be possible to extrapolate these results to a multicentre trial. Furthermore, although this study was designed to explore specifically critically ill patients with severe sepsis treated with adjuvant parenteral FOBLE infusion, the participants in each group were not necessarily limited in terms of their oral or enteral feeding, except for herbs and extra health food supplements. The ω-3 fatty acids in the normal diet that we provide in hospital are thought to be extremely low when compared with parenteral FOBLE treatment. A small amount of glucose water might have been infused to some individual patients. None of the patients received parenteral amino acid or lipid emulsion infusion other than 10% Omegaven, and the isonitrogenous energy and daily calories were not estimated for either group in our study. Although these might be considered to be confounders, we believe that the bias was negligible. Finally, the TNF-α and procalcitonin tests began midway through the study; therefore, the data were limited for some patients.
In conclusion, the present study indicates that administration of a 5-day course of parenteral FOBLE (10% Omegaven) as an adjuvant treatment in critically ill patients with severe sepsis is probably safe and helpful in terms of rapidly improving clinical severity. The results suggest that FOBLE is beneficial when clinically treating critically ill patients with sepsis.
